| 000 | 01757 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515123829.0 | ||
| 264 | 0 | _c20081117 | |
| 008 | 200811s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2008.05.069 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShah, Unmesh | |
| 245 | 0 | 0 |
_aDesign, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cJul 2008 |
||
| 300 |
_a4204-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenosine _xchemistry |
| 650 | 0 | 4 | _aAdenosine A2 Receptor Antagonists |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aChemistry, Pharmaceutical _xmethods |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aModels, Chemical |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPyrimidines _xchemical synthesis |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 |
_aTriazoles _xchemical synthesis |
| 650 | 0 | 4 |
_aWater _xchemistry |
| 700 | 1 | _aLankin, Claire M | |
| 700 | 1 | _aBoyle, Craig D | |
| 700 | 1 | _aChackalamannil, Samuel | |
| 700 | 1 | _aGreenlee, William J | |
| 700 | 1 | _aNeustadt, Bernard R | |
| 700 | 1 | _aCohen-Williams, Mary E | |
| 700 | 1 | _aHiggins, Guy A | |
| 700 | 1 | _aNg, Kwokei | |
| 700 | 1 | _aVarty, Geoffrey B | |
| 700 | 1 | _aZhang, Hongtao | |
| 700 | 1 | _aLachowicz, Jean E | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 18 _gno. 14 _gp. 4204-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2008.05.069 _zAvailable from publisher's website |
| 999 |
_c18043444 _d18043444 |
||